Cover Image

Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma

Bibliographic Details
Main Authors:	Gregora, E. (Author), Bacovsky, J. (Author), Minarik, J. (Author), Pour, L. (Author), Zemanova, M. (Author), Pavlicek, P. (Author), Pika, T. (Author), Scudla, V. (Author), Adam, Z. (Author)
Format:	Article
Language:	English

Similar Items

Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma
by: Bacovsky, J., et al.

The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma
by: Bojarska-Junak, A., et al.

Multiple myeloma multimedial education course
Published: (2011)

Multiple Myeloma and Paraproteinemias
by: Sakalová, Adriena, 1930-2020, et al.
Published: (1995)

Analysis of the serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and different stages of multiple myeloma
by: Bacovsky, J., et al.